Patient-derived, genome-edited and induced disease models
Human iPSC technology is an excellent tool to improve decision-making steps throughout the early stages of drug discovery. The main benefits of using human iPSC in disease modeling are that they retain patient-specific genetic backgrounds, can be genetically engineered and closely mimic human pathophysiology.
Disease modeling based on human iPSC-derived cells has the potential to revolutionize drug discovery. Nonetheless, significant expertise is required to overcome some technical and conceptual difficulties for the widespread implementation of these models in the pharmaceutical and biotechnology industry.
Partnering with a company that has expertise in human iPSC technology, can help fully leverage its advantages.